Business
BioCryst grants Neopharmed Gentili European rights to navenibart for hereditary angioedema, USD 345m deal
BioCryst Pharmaceuticals (Nasdaq: BCRX) has granted an Irish affiliate of Neopharmed Gentili exclusive rights to commercialize navenibart for hereditary...
Gyre Therapeutics completes USD 300m acquisition of Cullgen to create integrated US-China biotech company
Gyre Therapeutics (Nasdaq: GYRE) has completed the acquisition of Cullgen Inc., a privately held, clinical-stage biopharmaceutical company focused on...
Latus Bio closes USD 97m Series A financing for AAV gene therapy pipeline
Philadelphia-based Latus Bio has closed a USD 97 million Series A financing round to advance its AAV gene therapy pipeline, with lead programs targeting...
Bristol-Myers Squibb's CELMoD platform and admilparant advance toward pivotal readouts defining next-decade growth
Bristol-Myers Squibb held its BMY Q1 2026 earnings conference call on April 30, 2026, during which executives signaled that the company's late-stage...
Eli Lilly's Q1'26 Earnings Call: Retatrutide advances as post-incretin pipeline built around cell therapy acquisitions
Eli Lilly's Q1 2026 earnings conference call centered on retatrutide's first positive Phase III data in type 2 diabetes and a sweeping in vivo cell therapy...
Archimed acquires Esperion Therapeutics for USD 1.1b, gaining bempedoic acid commercial infrastructure
ARCHIMED has agreed to acquire Ann Arbor, Michigan-based Esperion Therapeutics (Nasdaq: ESPR) in a transaction valued at up to approximately USD 1.1 billion...
Ligand moving to terminate TR-Beta Program license with Viking Therapeutics over development breach
Ligand Pharmaceuticals (Nasdaq: LGND) has terminated its TR-Beta Program license with Viking Therapeutics (Nasdaq: VKTX), pulling rights to two small...
UCB acquires Candid Therapeutics for USD 2.2b to expand T-cell engager immunology platform
Belgium-based UCB (Euronext Brussels: UCB) has agreed to acquire San Diego-based Candid Therapeutics in a transaction valued at up to USD 2.2 billion,...
Seaport's Nasdaq IPO raises USD 254.9m
Seaport Therapeutics (Nasdaq: SPTX), a clinical-stage neuropsychiatric drug developer based in Boston, priced an upsized initial public offering of...
Summit’s ivonescimab heads toward November FDA decision as HARMONi-3 interim PFS misses threshold
Summit Therapeutics reported its Q1 2026 financial results on April 30, 2026, with the company's single asset, ivonescimab (SMT112), advancing toward a...
LEO Pharma bags Replay's HSV gene therapy platform for USD 50m upfront
Denmark-based LEO Pharma has entered into a definitive agreement to acquire San Diego-based Replay, a private gene therapy company, for USD 50 million...
Skyrizi combo doubles remission rates in refractory Crohn's disease, accelerating Phase III development
During AbbVie's Q1 2026 earnings conference call, held April 29, 2026, the single most consequential pipeline signal was the decision to accelerate Phase...
Novartis Q1'26 Earnings Call: Remibrutinib's MS readout key near-term growth determinant
During its Q1 2026 earnings conference call, held April 28, 2026, Novartis signaled that summer readouts for remibrutinib in relapsing multiple sclerosis...
OSR Holdings hands VEGF cancer vaccine to largest shareholder BCM Europe for up to USD 815m milestones
OSR Holdings (NASDAQ: OSRH) has entered a definitive global exclusive license agreement with BCM Europe AG (BCME) covering VXM01, a Phase 3-ready oral...
BeOne Medicines secures USD 2.02b option on Huahui Health trispecific antibody HH160
Huahui Health grants BeOne Medicines a global exclusive option over HH160, a preclinical trispecific antibody targeting PD-1, CTLA-4, and VEGF-A...
The AllSci Brief
Systematic R&D and deal news. Daily.